Teladoc Health president sells $69,632 in stock

Published 21/03/2025, 21:24
Teladoc Health president sells $69,632 in stock

Teladoc Health, Inc. (NYSE:TDOC), a telehealth company with a market capitalization of $1.47 billion, saw a notable transaction involving its President, International, Carlos Nueno. According to a recent SEC filing, Nueno sold 8,266 shares of common stock on March 20, 2025, at an average price of $8.424 per share. This transaction amounted to a total value of $69,632. InvestingPro analysis indicates the stock is currently trading below its Fair Value, with a "GOOD" overall financial health score.

Before the sale, Nueno acquired 18,225 shares of common stock on March 19, 2025, through the conversion of restricted stock units. These units converted on a one-for-one basis into common stock, as noted in the filing. The transaction comes as Teladoc prepares to report its next earnings on April 23, 2025.

The sale was executed to cover tax withholding obligations related to the vesting of Nueno’s restricted stock unit awards. Following these transactions, Nueno holds 12,891 shares of Teladoc common stock. The company’s shares have declined 46.5% over the past year, though InvestingPro data reveals several additional insights and tips available to subscribers, including detailed analysis in the comprehensive Pro Research Report covering this and 1,400+ other top US stocks.

In other recent news, Teladoc Health Inc. reported its fourth-quarter 2024 earnings, showing a revenue of $640.5 million, slightly above the forecast of $638.5 million, though its earnings per share (EPS) of -0.28 missed the expected -0.23. For the full year 2024, Teladoc’s revenue was $2.6 billion, a 1% decrease from the previous year. The company ended the year with $1.3 billion in cash and cash equivalents. Meanwhile, Teladoc has formed a partnership with Gifthealth, a pharmacy partner for Eli Lilly (NYSE:LLY)’s LillyDirect program, to improve access to Zepbound (tirzepatide) for members of its Comprehensive Weight Care Program. This collaboration aims to provide a more streamlined and affordable option for Teladoc Health members who lack insurance coverage for GLP-1s for obesity. Analyst firms such as Truist and Stifel have maintained their Hold ratings on Teladoc shares, with price targets of $10 and $9 respectively, reflecting a cautious outlook following the company’s mixed financial results and strategic partnerships. Additionally, Needham also reiterated a Hold rating after Teladoc’s mixed fourth-quarter results, citing uncertainties regarding the company’s future performance. These developments highlight Teladoc’s ongoing efforts to expand its service offerings while navigating financial challenges.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.